Therefore, the results demonstrate that AT9283 treatments, likely the MKK3 depletion, inhibit the AURKA nuclear localization, in the tested lines, suggesting AT9283 as MKDMA compound in CRC. This evidence concerns the gene AURKA and colorectal carcinoma.